# Insilico Medicine's AI-designed drug completes Phase IIa clinical trial

> Insilico Medicine has reported what may be a milestone for AI in medicine, a drug whose target and molecule were both chosen by generative AI has posted positive results in a Phase IIa human trial. The candidate, called Rentosertib, treats idiopathic pulmonary fibrosis, a serious scarring of the lungs with few good options. In a 71-patient study, people taking a 60mg daily dose saw mean lung function rise by 98.4 mL, while the placebo group declined by 20.3 mL. What makes the result stand out is not just the efficacy but the provenance. Insilico says this is the first peer-reviewed Phase IIa outcome in which both the disease target and the treating compound emerged from an end-to-end AI pipeline, its Pharma.AI platform, rather than conventional discovery. For years the promise of AI drug discovery has been mostly preclinical and promissory. A clean readout in real patients is different, it suggests AI-originated medicines can survive the move from computation into the clinic, the stage where most hopeful ideas quietly fail.

_Section: [Daily AI Updates](https://www.wortins.com/daily-ai) · Source: Tech Times · Published Sunday, July 12, 2026_

## Wortins' read

Insilico Medicine has reported what may be a milestone for AI in medicine, a drug whose target and molecule were both chosen by generative AI has posted positive results in a Phase IIa human trial. The candidate, called Rentosertib, treats idiopathic pulmonary fibrosis, a serious scarring of the lungs with few good options. In a 71-patient study, people taking a 60mg daily dose saw mean lung function rise by 98.4 mL, while the placebo group declined by 20.3 mL. What makes the result stand out is not just the efficacy but the provenance. Insilico says this is the first peer-reviewed Phase IIa outcome in which both the disease target and the treating compound emerged from an end-to-end AI pipeline, its Pharma.AI platform, rather than conventional discovery. For years the promise of AI drug discovery has been mostly preclinical and promissory. A clean readout in real patients is different, it suggests AI-originated medicines can survive the move from computation into the clinic, the stage where most hopeful ideas quietly fail.

## Source

[Read the full story at Tech Times](https://www.techtimes.com/articles/319136/20260626/ai-drug-discovery-reaches-clinical-proof-bio-2026-china-beat-biosecure-act-science.htm)

## Related coverage

- [Clearview AI Is Testing an AI Tool That Would Let Cops Unearth Your Life Online](https://www.wortins.com/story/clearview-ai-is-testing-an-ai-tool-that-would-let-cops-unear-8c573d0e) — [Wired](https://www.wired.com/story/clearview-ai-is-testing-an-ai-tool-that-lets-cops-instantly-unearth-your-online-activity/)
- [Powering AI is an architecture problem](https://www.wortins.com/story/powering-ai-is-an-architecture-problem-15281f16) — [MIT Technology Review](https://www.technologyreview.com/2026/09/10/1141649/powering-ai-is-an-architecture-problem/)
- [Inception launches Mercury 2.5 at 1,107 tokens per second](https://www.wortins.com/story/inception-launches-mercury-2-5-at-1-107-tokens-per-second-7999ed1b) — [TestingCatalog](https://www.testingcatalog.com/inception-launches-mercury-2-5-at-1-107-tokens-per-second/)
- [STAT+: Can AI fix the emergency room?](https://www.wortins.com/story/stat-can-ai-fix-the-emergency-room-a71d00ee) — [STAT](https://www.statnews.com/2026/09/09/scribe-emergency-room-fix-health-care-ai-prognosis/?utm_campaign=rss)
- [Top AI spenders cut per-employee costs by nearly 10 percent in August](https://www.wortins.com/story/top-ai-spenders-cut-per-employee-costs-by-nearly-10-percent--b31ffb0b) — [The Decoder](https://the-decoder.com/top-ai-spenders-cut-per-employee-costs-by-nearly-10-percent-in-august/)
- [Researchers used AI to build a WeChat worm that spreads through phone calls](https://www.wortins.com/story/researchers-used-ai-to-build-a-wechat-worm-that-spreads-thro-8bf3f469) — [The Next Web](https://thenextweb.com/news/wechat-worm-ai-calif-tencent-zero-click)

---

_Curated and written by [Wortins](https://www.wortins.com) — The daily AI briefing. Every story links to its original source; the "Wortins read" on each is our own original analysis. [About Wortins & our editorial approach](https://www.wortins.com/about)._